Genexine of South Korea Raises $70 Million for Novel Drug Portfolio

Genexine, a Korean biotech, raised $70 million from a combination of 14 Korean investors, its China partner Tasly Pharma and one other non-Korean investor. In 2015, Tasly acquired China rights for three novel Genexine drug candidates in a deal worth as much as $100 million, plus Tasly paid an unspecified amount for global rights to in-license two other drugs. Genexine, which has three drug candidates in clinical trials, focuses on treatments for cancer and orphan diseases based on its long-acting Fc fusion and therapeutic DNA technologies. More details.... Stock Symbols: (KOSDAQ: 095700) (SHA: 600535) Share this with colleagues: // //